SEC Form 4 · accession 0001179110-15-010898
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John C Martin
Officer — Chairman and CEO · Director
Period of report
Jul 1, 2015
Accepted (ET)
Jul 6, 2015 · 4:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 1, 2015 | M | 150,000 | $14.5025 | A | 4,364,492 | D | |
| Common StockF3 | Jul 1, 2015 | S | 92,260 | $115.9184 | D | 4,272,232 | D | |
| Common StockF4 | Jul 1, 2015 | S | 41,115 | $117.0646 | D | 4,231,117 | D | |
| Common StockF5,F6 | Jul 1, 2015 | S | 16,625 | $118.0101 | D | 4,214,492 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock option (right to buy)F2 | $14.5025 | Jul 1, 2015 | M | 150,000 | D | — | Jan 25, 2016 | Common Stock | 150,000 | 750,000 | D |
Explanation of responses
- F1The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- F2The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
- F3Sale prices reported for the transactions reported here range from $115.46 to $116.43. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- F4Sale prices reported for the transactions reported here range from $116.58 to $117.58. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- F5Sale prices reported for the transactions reported here range from $117.59 to $118.56. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- F6The number of shares reported as direct holdings reflects the correction of a past overstatement of 41,384 shares arising from a pre-2003 administrative reporting error. Stock splits in Sep 2004, June 2007 and Jan 2013 increased the original 5,173 share reporting error to 41,384 shares.